US12617777B2 - GPR84 antagonists and uses thereof - Google Patents

GPR84 antagonists and uses thereof

Info

Publication number
US12617777B2
US12617777B2 US17/649,752 US202217649752A US12617777B2 US 12617777 B2 US12617777 B2 US 12617777B2 US 202217649752 A US202217649752 A US 202217649752A US 12617777 B2 US12617777 B2 US 12617777B2
Authority
US
United States
Prior art keywords
compound
ring
nitrogen
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US17/649,752
Other languages
English (en)
Other versions
US20230113202A1 (en
Inventor
Shaun Abbott
Mylène De Léséleuc
Julien Martel
Elyse Bourque
Jeremy Green
Alexandre Larivée
Jean-Benoìt GIGUÈRE
Elodie LANDAGARAY
Claudio Sturino
Nadia Michel NASSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Green Chemistry Consulting LLC
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Priority to US17/649,752 priority Critical patent/US12617777B2/en
Publication of US20230113202A1 publication Critical patent/US20230113202A1/en
Assigned to Liminal Biosciences Limited reassignment Liminal Biosciences Limited ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: GREEN CHEMISTRY CONSULTING LLC
Assigned to Liminal Biosciences Limited reassignment Liminal Biosciences Limited ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: PARAZA PHARMA INC.
Assigned to Liminal Biosciences Limited reassignment Liminal Biosciences Limited ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: CALEDON RESEARCH AND DEVELOPMENT INC.
Assigned to Liminal Biosciences Limited reassignment Liminal Biosciences Limited ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: BOURQUE, ELYSE
Assigned to CALEDON RESEARCH AND DEVELOPMENT INC. reassignment CALEDON RESEARCH AND DEVELOPMENT INC. ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: ABBOTT, SHAUN, DE LÉSÉLEUC, Mylène, NASSER, Nadia Michel, MARTEL, Julien
Assigned to GREEN CHEMISTRY CONSULTING LLC reassignment GREEN CHEMISTRY CONSULTING LLC ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: GREEN, JEREMY
Assigned to PARAZA PHARMA INC. reassignment PARAZA PHARMA INC. ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: STURINO, CLAUDIO, LANDAGARAY, Elodie, GIGUÈRE, Jean-Benoît, LARIVÉE, Alexandre
Publication of US12617777B2 publication Critical patent/US12617777B2/en
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
US17/649,752 2021-02-02 2022-02-02 GPR84 antagonists and uses thereof Active US12617777B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/649,752 US12617777B2 (en) 2021-02-02 2022-02-02 GPR84 antagonists and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144720P 2021-02-02 2021-02-02
US17/649,752 US12617777B2 (en) 2021-02-02 2022-02-02 GPR84 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
US20230113202A1 US20230113202A1 (en) 2023-04-13
US12617777B2 true US12617777B2 (en) 2026-05-05

Family

ID=80683145

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/649,752 Active US12617777B2 (en) 2021-02-02 2022-02-02 GPR84 antagonists and uses thereof

Country Status (12)

Country Link
US (1) US12617777B2 (cg-RX-API-DMAC7.html)
EP (1) EP4288427A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024505571A (cg-RX-API-DMAC7.html)
KR (1) KR20230153387A (cg-RX-API-DMAC7.html)
CN (1) CN117098757A (cg-RX-API-DMAC7.html)
AU (1) AU2022216810A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015590A2 (cg-RX-API-DMAC7.html)
CA (1) CA3206501A1 (cg-RX-API-DMAC7.html)
IL (1) IL304701A (cg-RX-API-DMAC7.html)
MX (1) MX2023009060A (cg-RX-API-DMAC7.html)
TW (1) TW202246247A (cg-RX-API-DMAC7.html)
WO (1) WO2022167457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Gpr84アンタゴニストおよびその使用
JP7705966B2 (ja) * 2021-06-21 2025-07-10 武漢人福創新薬物研発中心有限公司 Gpr84アンタゴニストとしての三環式化合物
EP4565569A1 (en) * 2022-08-02 2025-06-11 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
EP4565568A1 (en) * 2022-08-02 2025-06-11 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
CN115785010A (zh) * 2022-11-23 2023-03-14 湖南大学 一类硫代1,2,3-三氮唑及其高效合成方法
CN118077649B (zh) * 2024-02-29 2024-09-10 复旦大学附属中山医院 一种免疫检查点抑制剂构建动脉粥样硬化小鼠模型的方法
WO2026132250A1 (en) 2024-12-18 2026-06-25 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof

Citations (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2020370A1 (en) 1989-07-06 1991-01-07 Peter Herold Pyrimidine derivatives
US5112839A (en) 1989-07-07 1992-05-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
EP0488532A1 (en) 1990-10-31 1992-06-03 E.R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
WO1993018029A1 (en) 1992-03-13 1993-09-16 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
WO1993020066A1 (en) 1992-04-03 1993-10-14 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5356911A (en) 1991-11-12 1994-10-18 Bayer Aktiengesellschaft Substituted biphenylpyridones
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
US5378720A (en) 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5407948A (en) 1993-05-13 1995-04-18 Bayer Aktiengesellschaft Substituted mono- and bipyridylmethylpyridones
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US5512576A (en) 1994-12-02 1996-04-30 Sterling Winthrop Inc. 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5869428A (en) 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them
WO1999052893A1 (en) 1998-04-08 1999-10-21 Novartis Ag N-pyridonyl herbicides
WO1999065901A1 (de) 1998-06-16 1999-12-23 Aventis Cropscience Gmbh 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003029210A2 (en) 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003047577A2 (en) 2001-12-06 2003-06-12 Eisai Co Ltd Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
WO2003051315A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2003051833A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2003053922A2 (en) 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2003059904A1 (en) 2001-12-21 2003-07-24 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
WO2003068230A1 (en) 2002-02-14 2003-08-21 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
US6642390B2 (en) 2001-07-11 2003-11-04 Lexicon Pharmaceuticals, Inc. One step synthesis of 1,2,3-triazole carboxylic acids
WO2003090699A1 (fr) 2002-04-23 2003-11-06 L'oreal Composition cosmetique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
WO2004030637A2 (en) 2002-10-01 2004-04-15 Merck & Co., Inc. Treatment of obesity and other disorders associated with excessive food intake
WO2004044046A2 (en) 2002-11-08 2004-05-27 Encysive Pharmaceuticals Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
WO2004054973A2 (en) 2002-12-18 2004-07-01 Novo Nordisk A/S Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
WO2004087677A2 (en) 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
WO2004089306A2 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2005018557A2 (en) 2003-08-13 2005-03-03 Pharmacia Corporation Substituted pyridinones
WO2005028439A1 (ja) 2003-09-17 2005-03-31 Sumitomo Chemical Company, Limited シンナモイル化合物およびその用途
WO2005070925A1 (de) 2004-01-25 2005-08-04 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2006030032A1 (en) 2004-09-17 2006-03-23 Janssen Pharmaceutica N.V. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2006058597A1 (de) 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyranderivate als antidiabetika
WO2006130403A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2006133147A2 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007006591A2 (fr) 2005-07-13 2007-01-18 Bayer Cropscience Sa Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations
WO2007018469A1 (en) 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
WO2007043835A1 (en) 2005-10-13 2007-04-19 Crystalgenomics, Inc. Fab i inhibitor and process for preparing same
WO2007062370A2 (en) 2005-11-22 2007-05-31 Smithkline Beecham Corporation Calcilytic compounds
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
WO2007083978A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
WO2007091176A1 (en) 2006-02-10 2007-08-16 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
WO2007104783A2 (en) 2006-03-15 2007-09-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators
WO2007132948A1 (ja) 2006-05-17 2007-11-22 Sumitomo Chemical Company, Limited シンナモイル化合物及びその用途
WO2007136125A1 (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Company, Limited 含複素環化合物及びその用途
WO2007143597A2 (en) 2006-06-05 2007-12-13 Novartis Ag Organic compounds
WO2008000697A1 (en) 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2008025886A1 (en) 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
WO2008030408A2 (en) 2006-09-05 2008-03-13 Yale University Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides
US7348334B2 (en) 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008107481A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008107480A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
WO2008107479A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
WO2008133896A2 (en) 2007-04-24 2008-11-06 Theravance, Inc. Dual-acting antihypertensive agents
WO2008143649A2 (en) 2006-12-04 2008-11-27 Dr. Reddy's Laboratories Limited Novel oxazolidinone compounds as antiinfective agents
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
WO2009016498A1 (en) 2007-08-02 2009-02-05 Pfizer Inc. Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
WO2009033704A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
WO2009087949A1 (ja) 2008-01-07 2009-07-16 Sumitomo Chemical Company, Limited 含複素環化合物及びその用途
WO2009121919A1 (en) 2008-04-02 2009-10-08 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2009137538A2 (en) 2008-05-08 2009-11-12 E. I. Du Pont De Nemours And Company Fungicidal substituted azoles
WO2010021693A2 (en) 2008-08-18 2010-02-25 Yale University Mif modulators
WO2010077582A1 (en) 2008-12-16 2010-07-08 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
US20100249092A1 (en) 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2010112437A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010131147A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
US20110045101A1 (en) 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
WO2011041461A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011057112A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
WO2011140202A2 (en) 2010-05-04 2011-11-10 Yale University Mif modulators
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2012011707A2 (en) 2010-07-23 2012-01-26 Hyundai Pharm Co., Ltd. Substituted pyridinone derivatives and methods for manufacturing the same
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012041158A1 (zh) 2010-09-29 2012-04-05 上海恒瑞医药有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012164085A1 (en) 2011-06-03 2012-12-06 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013092791A1 (en) 2011-12-22 2013-06-27 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
WO2014055548A1 (en) 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2014095798A1 (en) 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CA2809478A1 (en) 2013-03-13 2014-09-13 Queen's University At Kingston Luminescent compounds and methods of using same
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
WO2015058160A1 (en) 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
CN104844533A (zh) 2014-02-17 2015-08-19 中国医学科学院药物研究所 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
CN104876912A (zh) 2015-04-08 2015-09-02 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
WO2015134998A1 (en) 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
WO2015162216A1 (en) 2014-04-24 2015-10-29 Universita' Degli Studi Di Siena Biaryl amide or urea derivatives as trpv1 ligands
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 XIa 억제 활성을 가지는 신규한 화합물
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2015197550A1 (en) 2014-06-25 2015-12-30 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
WO2016058704A1 (de) 2014-10-17 2016-04-21 Scv Gmbh Konjugierte bisphosphonate für die diagnostik und therapie von knochenerkrankungen
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
KR101666759B1 (ko) 2015-08-06 2016-10-18 경북대학교 산학협력단 1-벤조피란메틸-1h-1,2,3-트리아졸 유도체 및 이의 용도
WO2016169911A1 (en) 2015-04-23 2016-10-27 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
CN106316975A (zh) 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
US9547197B2 (en) 2014-07-25 2017-01-17 Samsung Display Co., Ltd. Fabrication method of display device and display device
WO2017040459A1 (en) 2015-09-04 2017-03-09 Aunova Medchem LLC Improved solubility for target compounds
WO2017069601A1 (en) 2015-10-19 2017-04-27 Latvian Institute Of Organic Synthesis Substituted aminoalkylazoles as malarial aspartic protease inhibitors
WO2017132528A1 (en) 2016-01-29 2017-08-03 Bioventures, Llc Triazole derivatives of melampomagnolide b and methods of use thereof
WO2017207754A1 (en) 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
WO2018067615A1 (en) 2016-10-03 2018-04-12 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
EP3372590A1 (en) 2015-11-04 2018-09-12 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compounds having agonistic effect for gpr84, preparation method for compounds and use of compounds
WO2018195439A2 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
WO2018208985A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
WO2018227228A1 (en) 2017-06-13 2018-12-20 Commonwealth Scientific And Industrial Research Organisation Antiviral drugs
CN109369623A (zh) 2018-12-14 2019-02-22 山东大学 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
CN109456250A (zh) 2018-11-08 2019-03-12 哈尔滨医科大学 热激活延迟荧光(tadf)纳米探针及其制备方法和在生物成像中的应用
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019067702A1 (en) * 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
WO2019076329A1 (en) 2017-10-18 2019-04-25 Guochuan Emil Tsai INHIBITORS OF D-AMINO ACID OXIDASE AND THERAPEUTIC APPLICATIONS THEREOF
WO2019096944A1 (en) 2017-11-15 2019-05-23 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2019165158A1 (en) 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
CN110396089A (zh) 2018-04-24 2019-11-01 杭州健昵福生物科技有限公司 靶向肾型谷氨酰胺酶变构位点的化合物及应用
WO2020003313A1 (en) 2018-06-26 2020-01-02 Taumed R&D Ltd Epidural delivery device
WO2020006724A1 (zh) 2018-07-05 2020-01-09 清华大学 一种靶向降解fak蛋白的化合物及其应用
WO2020008013A1 (en) 2018-07-05 2020-01-09 Les Laboratoires Servier Amino-pyrimidonyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2020011811A1 (en) 2018-07-09 2020-01-16 Abivax Aryl-n-aryl derivatives for treating a rna virus infection
WO2020013646A1 (ko) 2018-07-12 2020-01-16 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
WO2020023846A1 (en) 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
WO2020020851A1 (en) 2018-07-24 2020-01-30 F. Hoffmann-La Roche Ag Reagent for mass spectrometry
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
WO2020055164A1 (ko) 2018-09-12 2020-03-19 크리스탈지노믹스(주) 7-하이드록시-4h-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도
WO2020118194A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
WO2020131597A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
US20200270231A1 (en) 2019-02-22 2020-08-27 Insilico Medicine Ip Limited Methods of inhibiting kinases
US20200331894A1 (en) 2017-10-18 2020-10-22 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2621144A1 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
WO2014139882A1 (en) 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof

Patent Citations (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2020370A1 (en) 1989-07-06 1991-01-07 Peter Herold Pyrimidine derivatives
EP0407342A2 (de) 1989-07-06 1991-01-09 Ciba-Geigy Ag Neue Pyrimidin Derivate
US5112839A (en) 1989-07-07 1992-05-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
EP0488532A1 (en) 1990-10-31 1992-06-03 E.R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
US5356911A (en) 1991-11-12 1994-10-18 Bayer Aktiengesellschaft Substituted biphenylpyridones
US5599823A (en) 1991-11-12 1997-02-04 Bayer Aktiengesellschaft Substituted biphenylpyridones
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
US5466701A (en) 1991-12-19 1995-11-14 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5378720A (en) 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
WO1993018029A1 (en) 1992-03-13 1993-09-16 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
US5510362A (en) 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
WO1993020066A1 (en) 1992-04-03 1993-10-14 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
US5607957A (en) 1992-04-03 1997-03-04 Merck Sharp & Dohme Ltd. Imidazole, triazole and tetrazole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5407948A (en) 1993-05-13 1995-04-18 Bayer Aktiengesellschaft Substituted mono- and bipyridylmethylpyridones
WO1996016952A1 (en) 1994-12-02 1996-06-06 Sanofi Winthrop, Inc. 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5512576A (en) 1994-12-02 1996-04-30 Sterling Winthrop Inc. 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5869428A (en) 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them
WO1999052893A1 (en) 1998-04-08 1999-10-21 Novartis Ag N-pyridonyl herbicides
US6265350B1 (en) 1998-06-16 2001-07-24 Hoechst Schering Agrevo Gmbh 1,3-oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides
WO1999065901A1 (de) 1998-06-16 1999-12-23 Aventis Cropscience Gmbh 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
US6670307B2 (en) 1998-06-16 2003-12-30 Hoechst Schering Agrevo Gmbh 1,3-oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides
US7939549B2 (en) 2000-06-12 2011-05-10 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
US7563811B2 (en) 2000-06-12 2009-07-21 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
US6949571B2 (en) 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
US7348334B2 (en) 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6642390B2 (en) 2001-07-11 2003-11-04 Lexicon Pharmaceuticals, Inc. One step synthesis of 1,2,3-triazole carboxylic acids
US7253190B2 (en) 2001-10-04 2007-08-07 Merck & Co., Inc. Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5
WO2003029210A2 (en) 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003047577A2 (en) 2001-12-06 2003-06-12 Eisai Co Ltd Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
US7759367B2 (en) 2001-12-06 2010-07-20 Eisai R&D Management Co., Ltd. Pharmaceutical compositions and their uses
WO2003051833A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2003051315A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
US7105548B2 (en) 2001-12-18 2006-09-12 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2003053922A2 (en) 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US20040259917A1 (en) 2001-12-19 2004-12-23 Cosford Nicholas D.P. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US7371767B2 (en) 2001-12-21 2008-05-13 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
WO2003059904A1 (en) 2001-12-21 2003-07-24 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US20070088033A1 (en) 2002-02-14 2007-04-19 Balekudru Devadas Diaryl Substituted Pyridinones
WO2003068230A1 (en) 2002-02-14 2003-08-21 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
US7067540B2 (en) 2002-02-14 2006-06-27 Pharmacia Corporation Substituted pyridinones
US7629363B2 (en) 2002-02-14 2009-12-08 Pfizer Inc Diaryl substituted pyridinones
WO2003090699A1 (fr) 2002-04-23 2003-11-06 L'oreal Composition cosmetique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
WO2004030637A2 (en) 2002-10-01 2004-04-15 Merck & Co., Inc. Treatment of obesity and other disorders associated with excessive food intake
US20070060608A1 (en) 2002-11-08 2007-03-15 Encysive Pharmaceuticals Inc. Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
WO2004044046A2 (en) 2002-11-08 2004-05-27 Encysive Pharmaceuticals Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US7799924B2 (en) 2002-12-18 2010-09-21 High Point Pharmaceuticals, Llc Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2004054973A2 (en) 2002-12-18 2004-07-01 Novo Nordisk A/S Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US7795271B2 (en) 2003-04-03 2010-09-14 Pharmacia Corporation Substituted pyrimidinones
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
WO2004087677A2 (en) 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidin-4-one derivatives and their use as p38 kinase modulators
US7268151B2 (en) 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2004089306A2 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2005018557A2 (en) 2003-08-13 2005-03-03 Pharmacia Corporation Substituted pyridinones
US20050176775A1 (en) 2003-08-13 2005-08-11 Balekudru Devadas Substituted pyridinones
US7989478B2 (en) 2003-09-17 2011-08-02 Sumitomo Chemical Company, Limited Cinnamoyl compound and use of the same
WO2005028439A1 (ja) 2003-09-17 2005-03-31 Sumitomo Chemical Company, Limited シンナモイル化合物およびその用途
US8299104B2 (en) 2004-01-25 2012-10-30 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2005070925A1 (de) 2004-01-25 2005-08-04 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US20130109652A1 (en) 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2006030032A1 (en) 2004-09-17 2006-03-23 Janssen Pharmaceutica N.V. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2006058597A1 (de) 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyranderivate als antidiabetika
US20070299065A1 (en) 2004-12-03 2007-12-27 Merck Patent Gmbh Tetrahydropyran Derivatives as Antidiabetics
WO2006130403A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
US20110281845A1 (en) 2005-06-08 2011-11-17 Novartis Ag Organic compounds
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
WO2006133147A2 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007006591A2 (fr) 2005-07-13 2007-01-18 Bayer Cropscience Sa Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations
WO2007018469A1 (en) 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
US20080280949A1 (en) 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
WO2007043835A1 (en) 2005-10-13 2007-04-19 Crystalgenomics, Inc. Fab i inhibitor and process for preparing same
WO2007062370A2 (en) 2005-11-22 2007-05-31 Smithkline Beecham Corporation Calcilytic compounds
US20090137557A1 (en) 2005-11-22 2009-05-28 Thomas Wen Fu Ku Calcilytic Compounds
US7998987B2 (en) 2005-11-30 2011-08-16 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007083978A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
US20090170847A1 (en) 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
WO2007091176A1 (en) 2006-02-10 2007-08-16 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
US20090270350A1 (en) 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
WO2007104783A2 (en) 2006-03-15 2007-09-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
WO2007132948A1 (ja) 2006-05-17 2007-11-22 Sumitomo Chemical Company, Limited シンナモイル化合物及びその用途
WO2007136125A1 (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Company, Limited 含複素環化合物及びその用途
WO2007143597A2 (en) 2006-06-05 2007-12-13 Novartis Ag Organic compounds
WO2008000697A1 (en) 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
WO2008025886A1 (en) 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
US8084471B2 (en) 2006-09-05 2011-12-27 Yale University Proteomimetic compounds as inhibitors of the interaction of nuclear receptor with coactivator peptides
WO2008030408A2 (en) 2006-09-05 2008-03-13 Yale University Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008143649A2 (en) 2006-12-04 2008-11-27 Dr. Reddy's Laboratories Limited Novel oxazolidinone compounds as antiinfective agents
US20100298384A1 (en) 2006-12-04 2010-11-25 Mohamed Takhi Novel oxazolidinone compounds as antiinfective agents
US8299101B2 (en) 2007-03-07 2012-10-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008107480A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
WO2008107479A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
WO2008107481A1 (en) 2007-03-07 2008-09-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8569351B2 (en) 2007-04-24 2013-10-29 Theravance, Inc. Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity
US8895755B2 (en) 2007-04-24 2014-11-25 Theravance Biopharma R&D Ip, Llc Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity
US8158659B2 (en) 2007-04-24 2012-04-17 Theravance, Inc. Dual-acting imidazole antihypertensive agents
US9150514B2 (en) 2007-04-24 2015-10-06 Theravance Biopharma R&D Ip, Llc Dual-acting antihypertensive agents
US8664254B2 (en) 2007-04-24 2014-03-04 Theravance, Inc. Dual-acting imidazole antihypertensive agents
US8236846B2 (en) 2007-04-24 2012-08-07 Theravance, Inc. Dual-acting antihypertensive agents
US7879896B2 (en) 2007-04-24 2011-02-01 Theravance, Inc. Dual-acting imidazole antihypertensive agents
US8349875B2 (en) 2007-04-24 2013-01-08 Theravance, Inc. Dual-acting antihypertensive agents
US9273008B2 (en) 2007-04-24 2016-03-01 Theravance Biopharma R&D Ip, Llc Dual-acting imidazole antihypertensive agents
US9012485B2 (en) 2007-04-24 2015-04-21 Theravance Biopharma R&D Ip, Llc Dual-acting imidazole antihypertensive agents
US8344013B2 (en) 2007-04-24 2013-01-01 Theravance, Inc. Dual-acting imidazole antihypertensive agents
US8013005B2 (en) 2007-04-24 2011-09-06 Theravance, Inc. Dual-acting antihypertensive agents
WO2008133896A2 (en) 2007-04-24 2008-11-06 Theravance, Inc. Dual-acting antihypertensive agents
US8242150B2 (en) * 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
WO2009016498A1 (en) 2007-08-02 2009-02-05 Pfizer Inc. Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US20200038391A1 (en) 2007-09-14 2020-02-06 Janssen Pharmaceuticals, Inc. 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones
WO2009033704A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
WO2009087949A1 (ja) 2008-01-07 2009-07-16 Sumitomo Chemical Company, Limited 含複素環化合物及びその用途
WO2009121919A1 (en) 2008-04-02 2009-10-08 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9096603B2 (en) 2008-04-02 2015-08-04 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators
US8623879B2 (en) 2008-04-02 2014-01-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators
WO2009137538A2 (en) 2008-05-08 2009-11-12 E. I. Du Pont De Nemours And Company Fungicidal substituted azoles
WO2009137651A2 (en) 2008-05-08 2009-11-12 E. I. Du Pont De Nemours And Company Fungicidal substituted azoles
US20100249092A1 (en) 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US10202343B2 (en) 2008-08-18 2019-02-12 Yale University MIF modulators
WO2010021693A2 (en) 2008-08-18 2010-02-25 Yale University Mif modulators
US20190270706A1 (en) 2008-08-18 2019-09-05 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US20110313001A1 (en) 2008-12-16 2011-12-22 Christian Fischer Triazole derivatives for treatment of alzheimer's disease
WO2010077582A1 (en) 2008-12-16 2010-07-08 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
WO2010112437A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9102679B2 (en) 2009-03-31 2015-08-11 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
US8623901B2 (en) 2009-03-31 2014-01-07 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
US20110045101A1 (en) 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles
WO2010131146A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
WO2010131147A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
US20120028931A1 (en) 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
WO2011041461A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US8778983B2 (en) 2009-10-01 2014-07-15 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US10000456B2 (en) 2009-10-01 2018-06-19 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011041462A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US8664220B2 (en) 2009-10-01 2014-03-04 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011057112A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
US20160122333A1 (en) 2010-03-30 2016-05-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
US20160256440A1 (en) 2010-03-30 2016-09-08 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US10653674B2 (en) 2010-03-30 2020-05-19 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US9533967B2 (en) 2010-03-30 2017-01-03 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US9963440B2 (en) 2010-03-30 2018-05-08 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
WO2011140202A2 (en) 2010-05-04 2011-11-10 Yale University Mif modulators
US20130253019A1 (en) 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2012011707A2 (en) 2010-07-23 2012-01-26 Hyundai Pharm Co., Ltd. Substituted pyridinone derivatives and methods for manufacturing the same
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
US9139565B2 (en) 2010-09-28 2015-09-22 Georgia Tech Research Corporation Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
WO2012041158A1 (zh) 2010-09-29 2012-04-05 上海恒瑞医药有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
US20130281503A1 (en) 2010-10-29 2013-10-24 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
US9272990B2 (en) 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012164085A1 (en) 2011-06-03 2012-12-06 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US10047083B2 (en) 2011-12-22 2018-08-14 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9255095B2 (en) 2011-12-22 2016-02-09 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2013092791A1 (en) 2011-12-22 2013-06-27 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US8927543B2 (en) 2011-12-22 2015-01-06 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
WO2014055548A1 (en) 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US20190321343A1 (en) 2012-10-02 2019-10-24 Intermune, Inc. Anti-Fibrotic Pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
WO2014095798A1 (en) 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
US9861637B2 (en) 2012-12-21 2018-01-09 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US9598367B2 (en) 2012-12-21 2017-03-21 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CA2809478A1 (en) 2013-03-13 2014-09-13 Queen's University At Kingston Luminescent compounds and methods of using same
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
US20200148703A1 (en) 2013-10-18 2020-05-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
US9115114B2 (en) 2013-10-18 2015-08-25 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
US10562915B2 (en) 2013-10-18 2020-02-18 Celgene Quanticel Research, Inc. Bromodomain inhibitors
US10023592B2 (en) 2013-10-18 2018-07-17 Celgene Quanticel Research, Inc. Bromodomain inhibitors
US9598372B2 (en) 2013-10-18 2017-03-21 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015058160A1 (en) 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
US9034900B2 (en) 2013-10-18 2015-05-19 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
CN104844533A (zh) 2014-02-17 2015-08-19 中国医学科学院药物研究所 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
CN104844533B (zh) 2014-02-17 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
US10125102B2 (en) 2014-03-07 2018-11-13 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10633345B2 (en) 2014-03-07 2020-04-28 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
WO2015134998A1 (en) 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10689346B2 (en) 2014-03-07 2020-06-23 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10329260B2 (en) 2014-03-07 2019-06-25 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
WO2015162216A1 (en) 2014-04-24 2015-10-29 Universita' Degli Studi Di Siena Biaryl amide or urea derivatives as trpv1 ligands
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 XIa 억제 활성을 가지는 신규한 화합물
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2015197550A1 (en) 2014-06-25 2015-12-30 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20190209548A1 (en) 2014-07-22 2019-07-11 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
US10130625B2 (en) 2014-07-22 2018-11-20 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
US9547197B2 (en) 2014-07-25 2017-01-17 Samsung Display Co., Ltd. Fabrication method of display device and display device
WO2016058704A1 (de) 2014-10-17 2016-04-21 Scv Gmbh Konjugierte bisphosphonate für die diagnostik und therapie von knochenerkrankungen
US10508127B2 (en) 2014-10-17 2019-12-17 Scv Gmbh Conjugated bisphosphonates for the diagnosis and therapy of bone diseases
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
CN104876912A (zh) 2015-04-08 2015-09-02 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
US10568879B2 (en) 2015-04-23 2020-02-25 Galapagos Nv Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016169911A1 (en) 2015-04-23 2016-10-27 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN106316975A (zh) 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
KR101666759B1 (ko) 2015-08-06 2016-10-18 경북대학교 산학협력단 1-벤조피란메틸-1h-1,2,3-트리아졸 유도체 및 이의 용도
WO2017040459A1 (en) 2015-09-04 2017-03-09 Aunova Medchem LLC Improved solubility for target compounds
WO2017069601A1 (en) 2015-10-19 2017-04-27 Latvian Institute Of Organic Synthesis Substituted aminoalkylazoles as malarial aspartic protease inhibitors
EP3372590A1 (en) 2015-11-04 2018-09-12 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compounds having agonistic effect for gpr84, preparation method for compounds and use of compounds
US10428082B2 (en) 2016-01-29 2019-10-01 Bioventures, Llc Triazole derivatives of melampomagnolide B and methods of use thereof
WO2017132528A1 (en) 2016-01-29 2017-08-03 Bioventures, Llc Triazole derivatives of melampomagnolide b and methods of use thereof
US20190209656A1 (en) 2016-06-02 2019-07-11 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
WO2017207754A1 (en) 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
US20200039943A1 (en) 2016-10-03 2020-02-06 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
WO2018067615A1 (en) 2016-10-03 2018-04-12 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
WO2018195439A2 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
US20200247762A1 (en) 2017-04-20 2020-08-06 The Regents Of The University Of California K-ras modulators
WO2018208985A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
US20200255413A1 (en) 2017-05-10 2020-08-13 Forge Therapeutics, Inc. Antibacterial compounds
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
WO2018210822A1 (en) 2017-05-16 2018-11-22 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
WO2018227228A1 (en) 2017-06-13 2018-12-20 Commonwealth Scientific And Industrial Research Organisation Antiviral drugs
US20200206196A1 (en) 2017-06-13 2020-07-02 Commonwealth Scientific And Industrial Research Organisation Antiviral Drugs
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019067702A1 (en) * 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US10336724B2 (en) 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
WO2019076329A1 (en) 2017-10-18 2019-04-25 Guochuan Emil Tsai INHIBITORS OF D-AMINO ACID OXIDASE AND THERAPEUTIC APPLICATIONS THEREOF
US20200331894A1 (en) 2017-10-18 2020-10-22 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
WO2019096944A1 (en) 2017-11-15 2019-05-23 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2019165158A1 (en) 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
CN110396089A (zh) 2018-04-24 2019-11-01 杭州健昵福生物科技有限公司 靶向肾型谷氨酰胺酶变构位点的化合物及应用
WO2020003313A1 (en) 2018-06-26 2020-01-02 Taumed R&D Ltd Epidural delivery device
WO2020008013A1 (en) 2018-07-05 2020-01-09 Les Laboratoires Servier Amino-pyrimidonyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2020006724A1 (zh) 2018-07-05 2020-01-09 清华大学 一种靶向降解fak蛋白的化合物及其应用
WO2020011812A1 (en) 2018-07-09 2020-01-16 Abivax Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating rna virus infection
WO2020011816A1 (en) 2018-07-09 2020-01-16 Abivax Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating a rna virus infection
WO2020011811A1 (en) 2018-07-09 2020-01-16 Abivax Aryl-n-aryl derivatives for treating a rna virus infection
WO2020013646A1 (ko) 2018-07-12 2020-01-16 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
WO2020020851A1 (en) 2018-07-24 2020-01-30 F. Hoffmann-La Roche Ag Reagent for mass spectrometry
WO2020023846A1 (en) 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
WO2020033413A3 (en) 2018-08-07 2020-05-07 Tosk, Inc. Modulators of ras gtpase
WO2020055164A1 (ko) 2018-09-12 2020-03-19 크리스탈지노믹스(주) 7-하이드록시-4h-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도
CN109456250A (zh) 2018-11-08 2019-03-12 哈尔滨医科大学 热激活延迟荧光(tadf)纳米探针及其制备方法和在生物成像中的应用
US20200331874A1 (en) 2018-12-07 2020-10-22 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
WO2020118194A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
CN109369623B (zh) 2018-12-14 2020-04-21 山东大学 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
CN109369623A (zh) 2018-12-14 2019-02-22 山东大学 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
WO2020131597A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
WO2020170202A1 (en) 2019-02-22 2020-08-27 Insilico Medicine Ip Limited Kinase inhibitors
US20200270234A1 (en) 2019-02-22 2020-08-27 Insilico Medicine Ip Limited Kinase inhibitors
WO2020170203A1 (en) 2019-02-22 2020-08-27 Insilico Medicine Ip Limited Methods of inhibiting kinases
US20200270231A1 (en) 2019-02-22 2020-08-27 Insilico Medicine Ip Limited Methods of inhibiting kinases
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof

Non-Patent Citations (128)

* Cited by examiner, † Cited by third party
Title
Al Mahmud, Z. et al., "Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84," Scientific Reports, pp. 1-15 (2017).
Alavi in "The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: A review," Life Sciences 224 2019) 33-40.
Ando, M. et al., "Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists," Bioorganic & Medicinal Chemistry Letters vol. 19, pp. 5186-5190 (2009).
Bae in Cancer Targeted Drug Delivery, Springer: New York, 2013, Page v.
Bendele in "Animal models of rheumatoid arthritis" J Musculoskel Neuron Interact 2001; 1(4):377-385.
Bouchard C., et al. in "G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions." Glia. 2007; 55(8):790-800.
Carlo C. Maley and Mel Greaves in Frontiers in Cancer Research, Springer: 2016, pp. 18-19.
Chen in "Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists" J. Med. Chem. 2020, 63, 1539915409.
Cosin-Roger, J. et al., "Metabolite Sensing CPCRs: Promising Therapeutic Targets for Cancer Treatment," Cells, vol. 9, pp. 1-33 (2020).
Costigan in "Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage," Annu. Rev. Neurosci. 2009. 32:1-32.
Damia in "Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models?" European Journal of Cancer (2009) vol. 45, pp. 2768-2781.
Desrivot in "Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies" Clinical Pharmacology in Drug Development 2021, 10(9) 1007-1017.
Dietrich, P.A., et .al., "GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis," Blood, vol. 124, No. 22, pp. 3284-3294 (2013).
Elborn in "Cystic fibrosis" The Lancet, Published online Apr. 29, 2016, Online "http://dx.doi.org/10.1016/S0140-6736(16)00576-6" 1-13.
Fredriksson, R. et al., "The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints," Mol. Pharmacol., vol. 63, No. 6, pp. 1256-1272 (2003).
Gagnon, L., et al. in "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84." American J. of Path., 2018, 188(5); 1132-1148.
Gamo, K. et al., "G-Protein-Coupled Receptor Screen Reveals a Role for Chemokine Receptor CCR5 in Suppressing Microglial Neurotoxicity," The Journal of Neuroscience, 28(46), pp. 11980-11988 (2008).
Hayat, M.A. in Autophagy Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging vol. 5 Academic Press: San Diego, 2015, p. xxi.
International Search Report and Written Opinion for International Application No. PCT/EP2022/052400, dated Jul. 27, 2022.
International Search Report and Written Opinion for International Application No. PCT/EP2022/052419, dated Jul. 11, 2022.
Jenkins, L. et al., "Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84." ACS Pharmacology & Translational Science, 2021, 4(5): 1598-1613.
Johnson, et al. "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials." British Journal of Cancer 2001, 84, 1424-1431.
Kalisiak et al. Organic Letters, 2008, vol. 10, No. 15, 3171-3174. *
Kalisiak, J. et al., "Efficient Synthesis of 2-Substituted-1,2,3-triazoles," Org. Lett., 10(15):3171-3174 (2008).
Labeguère F., et al. in "Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6, 1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial." J Med Chem. 2020; 63(22):13526-13545.
Labeguere, F et al., "Discovery of 9-Cyclopropylethynyl-2-((S-1-[1,4]dioxan-2-ylmethoxy)-6,7- dihydropyrimido[6, 1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial," J. Med. Chem., vol. 63, pp. 13526-13545 (2020).
Le Bars, et al. in "Animal Models of Nociception," Pharmacological Reviews 2001, 53, 597-652, at p. 634.
Ledford in "US cancer institute overhauls cell lines" Nature Feb. 25, 2016, vol. 530, p. 391.
Lee, D. et al., "Efficient Syntheses of 1,2,3-Triazoloamide Derivatives Using Solid- and Solution-Phase Synthetic Approaches," Molecules, vol. 20, No. 11, (2015) pp. 19984-20013.
Luscombe in "20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor ?" DNA and Cell Biology (2020), vol. 39(11), pp. 1926-1937.
Luscombe V. B., et al. in "20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?" DNA Cell Biol., vol. 39, No. 11 (2020) pp. 1926-1937.
Mancini, S.J. et al., "On-target and off-target effects of novel orthosteric and allosteric activators of GPR84," Scientific Reports, vol. 9, pp. 1-15 (2019).
Marsango in "Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84" Br J Pharmacol. 2022;179:35293541.
Mohammadi, L. et al., "Synthesis of nanomagnetic supported thiourea-copper(I) catalyst and its application the syntheses of triazoles and benzamides," Applied Organometallic Chemistry, Longman Group UK, Ltd, Hoboken, USA, vol. 32, No. 1 (2017).
Nanthakumar, C.B. et al., "Dissecting fibrosis: therapeutic insights from the small-molecule toolbox," Nature Reviews, vol. 14, pp. 693-720 (2015).
News & Analysis, BioBusiness Briefs, Target Watch, "GPR84: an immune response dial," vol. 19, p. 374 (2020).
Nguyen Q. T., et al. in "PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure." Cardiovasc Res. 2020; 116(1):171-182.
Nicol, L. S., et al. in "The role of G-protein receptor 84 in experimental neuropathic pain." J. Neurosci. 2015; 35(23):8959-69.
Ocana, A. in "Preclinical development of molecular targeted agents for cancer" Nat. Rev. Clin. Oncol. 2011, 8, 200-209.
Partial International Search Report for International Application PCT/EP/2022/052400 dated May 10, 2022.
Partial International Search Report for International Application PCT/EP/2022/052419 dated May 20, 2022.
Puengel, T., et al. in "The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis." J Clin Med. 2020; 9(4):1140.
Raghu G. and Selman, M. "Nintedanib and Pirfenidone, New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions," Am. J. Resp. and Crit. Care Med., vol. 191, No. 3, pp. 252-254 (2015).
Recio C., et al. in "Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages." Front Immunol. 2018; 9:1419.
Reddy, N. et al., "Dual catalysis by Cu(i): facile single step click and intramolecular C—O bond formation leading to triazole tethered dihydrobenzodioxines/benzoxazines/benzoxathiines/ benzodioxepines," Organic & Biomolecular Chemistry, vol. 11, No. 42, pp. 7350-7360 (2013).
Registry No. 1043552-81-3, File Registry on STN, entered STN Aug. 25, 2008. *
Registry No. 208990-89-0, File Registry on STN, entered STN Jul. 26, 1998. *
Registry No. 876592-08-4, File Registry on STN, entered STN Mar. 13, 2006. *
Schober in "New Advances in the Treatment of Metastatic Pancreatic Cancer" Digestion 2015; vol. 92, pp. 175-184.
Sharma in "Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents" Nature Reviews Cancer, Apr. 2010, vol. 10, pp. 241-253.
Simard, J. C., et al. in "Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease." Sci Rep. 2020; 10, 12778.
STN Registry Database, Registry No. 1043552-81-3 for "4-[4-(1,1-Dimethylethyl)phenyl]-1H-1,2,3- triazole-1-methanol," entered on Aug. 25, 2008, 3 pages.
STN Registry Database, Registry No. 876592-08-4 for "4-Phenyl-1H-1,2,3-triazole-1-methanol" entered on Mar. 13, 2006, 3 pages.
Thanigaimalai, P. et al., ("6-(Ar)Alkylamino-Substituted Uracil Derivatives: Lipid Mimetics with Potent Activity at the Orphan G Protein-Coupled Receptor 84 (GPR84)," ACS Omega, vol. 3, No. 3, pp. 3365-3383 (2018).
Tomohiro Chiba in "Emerging Therapeutic Strategies in Alzheimer's Disease" Intech 2013, 181-225.
Torkildsen in "Disease-modifying treatments for multiple sclerosis—a review of approved medications" European Journal of Neurology 2015, 23 (Suppl. 1):18-27.
University of Cambridge John van Geest Centre for Brain Repair School of Clinical Medicine "Alzheimer's disease and tauopathy" Online "http://www.brc.cam.ac.uk/research/alzheimers-disease-and-tauopathy/" accessed Sep. 10, 2015.
Vincetti, P. et al., "Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5—NS3 Interaction and the Host Src/Fyn Kinases," J. Med. Chem., vol. 58, pp. 4964-4975 (2015).
Vincetti, P. et al., "Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5—NS3 Interaction and the Host Src/Fyn Kinases," Journal of Medicinal Chemistry, vol. 58, No. 12 (2015) pp. 4964-4975.
Wacker, D. et al., "How ligands illuminate GPCR molecular pharmacology," Cell, pp. 1-29, (2017).
Wei L., et al. in "Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia." J Neuroinflammation. 2017;14(1):198.
Yin, C. et al. in "Regulatory role of Gpr84 in the switch of alveolar macrophages from CD11blo to CD11bhi status during lung injury process." Mucosal Immun. 2020; 13(6): 892-907.
Yu, J. et al., "Synthesis and antitumor activity of novel 2,3-diethanethio-2,3,5-trideoxy-5-triazolo nucleoside anlogues," European J. Med. Chem., Elsevier, Amsterdam, NL, vol. 45, No. 7, pp. 3219-3222 (2010).
Zhao in "Vaccine adjuvants: mechanisms and platforms" Signal Transduction and Targeted Therapy (2023) vol. 8, p. 283.
Al Mahmud, Z. et al., "Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84," Scientific Reports, pp. 1-15 (2017).
Alavi in "The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: A review," Life Sciences 224 2019) 33-40.
Ando, M. et al., "Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists," Bioorganic & Medicinal Chemistry Letters vol. 19, pp. 5186-5190 (2009).
Bae in Cancer Targeted Drug Delivery, Springer: New York, 2013, Page v.
Bendele in "Animal models of rheumatoid arthritis" J Musculoskel Neuron Interact 2001; 1(4):377-385.
Bouchard C., et al. in "G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions." Glia. 2007; 55(8):790-800.
Carlo C. Maley and Mel Greaves in Frontiers in Cancer Research, Springer: 2016, pp. 18-19.
Chen in "Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists" J. Med. Chem. 2020, 63, 1539915409.
Cosin-Roger, J. et al., "Metabolite Sensing CPCRs: Promising Therapeutic Targets for Cancer Treatment," Cells, vol. 9, pp. 1-33 (2020).
Costigan in "Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage," Annu. Rev. Neurosci. 2009. 32:1-32.
Damia in "Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models?" European Journal of Cancer (2009) vol. 45, pp. 2768-2781.
Desrivot in "Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies" Clinical Pharmacology in Drug Development 2021, 10(9) 1007-1017.
Dietrich, P.A., et .al., "GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis," Blood, vol. 124, No. 22, pp. 3284-3294 (2013).
Elborn in "Cystic fibrosis" The Lancet, Published online Apr. 29, 2016, Online "http://dx.doi.org/10.1016/S0140-6736(16)00576-6" 1-13.
Fredriksson, R. et al., "The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints," Mol. Pharmacol., vol. 63, No. 6, pp. 1256-1272 (2003).
Gagnon, L., et al. in "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84." American J. of Path., 2018, 188(5); 1132-1148.
Gamo, K. et al., "G-Protein-Coupled Receptor Screen Reveals a Role for Chemokine Receptor CCR5 in Suppressing Microglial Neurotoxicity," The Journal of Neuroscience, 28(46), pp. 11980-11988 (2008).
Hayat, M.A. in Autophagy Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging vol. 5 Academic Press: San Diego, 2015, p. xxi.
International Search Report and Written Opinion for International Application No. PCT/EP2022/052400, dated Jul. 27, 2022.
International Search Report and Written Opinion for International Application No. PCT/EP2022/052419, dated Jul. 11, 2022.
Jenkins, L. et al., "Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84." ACS Pharmacology & Translational Science, 2021, 4(5): 1598-1613.
Johnson, et al. "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials." British Journal of Cancer 2001, 84, 1424-1431.
Kalisiak et al. Organic Letters, 2008, vol. 10, No. 15, 3171-3174. *
Kalisiak, J. et al., "Efficient Synthesis of 2-Substituted-1,2,3-triazoles," Org. Lett., 10(15):3171-3174 (2008).
Labeguère F., et al. in "Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6, 1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial." J Med Chem. 2020; 63(22):13526-13545.
Labeguere, F et al., "Discovery of 9-Cyclopropylethynyl-2-((S-1-[1,4]dioxan-2-ylmethoxy)-6,7- dihydropyrimido[6, 1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial," J. Med. Chem., vol. 63, pp. 13526-13545 (2020).
Le Bars, et al. in "Animal Models of Nociception," Pharmacological Reviews 2001, 53, 597-652, at p. 634.
Ledford in "US cancer institute overhauls cell lines" Nature Feb. 25, 2016, vol. 530, p. 391.
Lee, D. et al., "Efficient Syntheses of 1,2,3-Triazoloamide Derivatives Using Solid- and Solution-Phase Synthetic Approaches," Molecules, vol. 20, No. 11, (2015) pp. 19984-20013.
Luscombe in "20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor ?" DNA and Cell Biology (2020), vol. 39(11), pp. 1926-1937.
Luscombe V. B., et al. in "20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?" DNA Cell Biol., vol. 39, No. 11 (2020) pp. 1926-1937.
Mancini, S.J. et al., "On-target and off-target effects of novel orthosteric and allosteric activators of GPR84," Scientific Reports, vol. 9, pp. 1-15 (2019).
Marsango in "Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84" Br J Pharmacol. 2022;179:35293541.
Mohammadi, L. et al., "Synthesis of nanomagnetic supported thiourea-copper(I) catalyst and its application the syntheses of triazoles and benzamides," Applied Organometallic Chemistry, Longman Group UK, Ltd, Hoboken, USA, vol. 32, No. 1 (2017).
Nanthakumar, C.B. et al., "Dissecting fibrosis: therapeutic insights from the small-molecule toolbox," Nature Reviews, vol. 14, pp. 693-720 (2015).
News & Analysis, BioBusiness Briefs, Target Watch, "GPR84: an immune response dial," vol. 19, p. 374 (2020).
Nguyen Q. T., et al. in "PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure." Cardiovasc Res. 2020; 116(1):171-182.
Nicol, L. S., et al. in "The role of G-protein receptor 84 in experimental neuropathic pain." J. Neurosci. 2015; 35(23):8959-69.
Ocana, A. in "Preclinical development of molecular targeted agents for cancer" Nat. Rev. Clin. Oncol. 2011, 8, 200-209.
Partial International Search Report for International Application PCT/EP/2022/052400 dated May 10, 2022.
Partial International Search Report for International Application PCT/EP/2022/052419 dated May 20, 2022.
Puengel, T., et al. in "The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis." J Clin Med. 2020; 9(4):1140.
Raghu G. and Selman, M. "Nintedanib and Pirfenidone, New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions," Am. J. Resp. and Crit. Care Med., vol. 191, No. 3, pp. 252-254 (2015).
Recio C., et al. in "Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages." Front Immunol. 2018; 9:1419.
Reddy, N. et al., "Dual catalysis by Cu(i): facile single step click and intramolecular C—O bond formation leading to triazole tethered dihydrobenzodioxines/benzoxazines/benzoxathiines/ benzodioxepines," Organic & Biomolecular Chemistry, vol. 11, No. 42, pp. 7350-7360 (2013).
Registry No. 1043552-81-3, File Registry on STN, entered STN Aug. 25, 2008. *
Registry No. 208990-89-0, File Registry on STN, entered STN Jul. 26, 1998. *
Registry No. 876592-08-4, File Registry on STN, entered STN Mar. 13, 2006. *
Schober in "New Advances in the Treatment of Metastatic Pancreatic Cancer" Digestion 2015; vol. 92, pp. 175-184.
Sharma in "Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents" Nature Reviews Cancer, Apr. 2010, vol. 10, pp. 241-253.
Simard, J. C., et al. in "Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease." Sci Rep. 2020; 10, 12778.
STN Registry Database, Registry No. 1043552-81-3 for "4-[4-(1,1-Dimethylethyl)phenyl]-1H-1,2,3- triazole-1-methanol," entered on Aug. 25, 2008, 3 pages.
STN Registry Database, Registry No. 876592-08-4 for "4-Phenyl-1H-1,2,3-triazole-1-methanol" entered on Mar. 13, 2006, 3 pages.
Thanigaimalai, P. et al., ("6-(Ar)Alkylamino-Substituted Uracil Derivatives: Lipid Mimetics with Potent Activity at the Orphan G Protein-Coupled Receptor 84 (GPR84)," ACS Omega, vol. 3, No. 3, pp. 3365-3383 (2018).
Tomohiro Chiba in "Emerging Therapeutic Strategies in Alzheimer's Disease" Intech 2013, 181-225.
Torkildsen in "Disease-modifying treatments for multiple sclerosis—a review of approved medications" European Journal of Neurology 2015, 23 (Suppl. 1):18-27.
University of Cambridge John van Geest Centre for Brain Repair School of Clinical Medicine "Alzheimer's disease and tauopathy" Online "http://www.brc.cam.ac.uk/research/alzheimers-disease-and-tauopathy/" accessed Sep. 10, 2015.
Vincetti, P. et al., "Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5—NS3 Interaction and the Host Src/Fyn Kinases," J. Med. Chem., vol. 58, pp. 4964-4975 (2015).
Vincetti, P. et al., "Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5—NS3 Interaction and the Host Src/Fyn Kinases," Journal of Medicinal Chemistry, vol. 58, No. 12 (2015) pp. 4964-4975.
Wacker, D. et al., "How ligands illuminate GPCR molecular pharmacology," Cell, pp. 1-29, (2017).
Wei L., et al. in "Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia." J Neuroinflammation. 2017;14(1):198.
Yin, C. et al. in "Regulatory role of Gpr84 in the switch of alveolar macrophages from CD11blo to CD11bhi status during lung injury process." Mucosal Immun. 2020; 13(6): 892-907.
Yu, J. et al., "Synthesis and antitumor activity of novel 2,3-diethanethio-2,3,5-trideoxy-5-triazolo nucleoside anlogues," European J. Med. Chem., Elsevier, Amsterdam, NL, vol. 45, No. 7, pp. 3219-3222 (2010).
Zhao in "Vaccine adjuvants: mechanisms and platforms" Signal Transduction and Targeted Therapy (2023) vol. 8, p. 283.

Also Published As

Publication number Publication date
MX2023009060A (es) 2023-09-29
CN117098757A (zh) 2023-11-21
US20230113202A1 (en) 2023-04-13
EP4288427A1 (en) 2023-12-13
TW202246247A (zh) 2022-12-01
KR20230153387A (ko) 2023-11-06
CA3206501A1 (en) 2022-08-11
JP2024505571A (ja) 2024-02-06
IL304701A (en) 2023-09-01
WO2022167457A1 (en) 2022-08-11
AU2022216810A1 (en) 2023-08-24
BR112023015590A2 (pt) 2023-10-17

Similar Documents

Publication Publication Date Title
US12168057B2 (en) IRAK degraders and uses thereof
US12624044B2 (en) SMARCA degraders and uses thereof
US12545659B2 (en) IRAK degraders and uses thereof
US12150995B2 (en) IRAK degraders and uses thereof
US12091411B2 (en) IRAK degraders and uses thereof
US11352350B2 (en) IRAK degraders and uses thereof
US10562906B2 (en) TYK2 inhibitors and uses thereof
US11414431B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
US20250197387A1 (en) Bcl-xl degraders and uses thereof
US20230113202A1 (en) Gpr84 antagonists and uses thereof
US20230303526A1 (en) Irak degraders and uses thereof
US20250179075A1 (en) Mk2 degraders and uses thereof
US12378229B2 (en) GPR84 antagonists and uses thereof
US20260055117A1 (en) Substituted pyridone gpr84 antagonists and uses thereof
TW202415650A (zh) 芳基-三唑基及相關gpr84拮抗劑及其用途
US20250154145A1 (en) Oxer1 antagonists and uses thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: LIMINAL BIOSCIENCES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PARAZA PHARMA INC.;REEL/FRAME:068653/0345

Effective date: 20240715

Owner name: LIMINAL BIOSCIENCES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREEN CHEMISTRY CONSULTING LLC;REEL/FRAME:068653/0341

Effective date: 20240507

Owner name: LIMINAL BIOSCIENCES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CALEDON RESEARCH AND DEVELOPMENT INC.;REEL/FRAME:068653/0337

Effective date: 20240820

Owner name: LIMINAL BIOSCIENCES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOURQUE, ELYSE;REEL/FRAME:068653/0332

Effective date: 20240428

Owner name: CALEDON RESEARCH AND DEVELOPMENT INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABBOTT, SHAUN;DE LESELEUC, MYLENE;MARTEL, JULIEN;AND OTHERS;SIGNING DATES FROM 20240424 TO 20240425;REEL/FRAME:068653/0323

Owner name: GREEN CHEMISTRY CONSULTING LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREEN, JEREMY;REEL/FRAME:068653/0318

Effective date: 20240507

Owner name: PARAZA PHARMA INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARIVEE, ALEXANDRE;GIGUERE, JEAN-BENOIT;LANDAGARAY, ELODIE;AND OTHERS;SIGNING DATES FROM 20240425 TO 20240711;REEL/FRAME:068653/0310

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE